TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$30.00
-0.25 (-0.84%)
▼
5d:
+0.72%
30d:
-8.86%
90d:
-3.89%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 29, 2026
26d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TEVA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TEVA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.22
Based on 9.7% avg growth
INTRINSIC VALUE TODAY
$32.43
7.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $30.00, which is considered fair relative to its 30-day fair value range of $28.96 to $32.76. The stock's valuation (Forward PE: 9.8) is in line with its historical norms (10.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This pessimistic expectation contrasts with the company's recent 40.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $30.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.82 (+25.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $30.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.82 (+25.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$28.96 -
$32.76
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.0% below Wall St target ($37.82)
Fair Price Analysis
30-Day Fair Range
$28.96 -
$32.76
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$28.29
Resistance Level
$30.71
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.79
Wall Street Target
$37.82
(+25.0%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
40.0%
Profit Margin
8.2%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
9.8 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$29.34
(-3%)
2-Year Target
$28.46
(-6%)
3-Year Target
$27.61
(-9%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$30.17
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 15.3%)
$105.85
(+250%)
Base:
(SPY PE: 9.8, Growth: 15.3%)
$46.37
(+53%)
Bear:
(PE: 8.3, Growth: 15.3%)
$39.42
(+30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 23.74 | Current EPS (TTM): $1.21
Bull Case
$63.21
(+120%)
Analyst growth 100.0%, PE expands to 26.1
Base Case
$57.46
(+100%)
Market implied 100.0%, PE stable at 23.7
Bear Case
$19.54
(-32%)
Severe decline -20.0%, PE contracts to 20.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 10.7
Stabilization Target:
$33.06
(+9.3%)
PE Expansion Potential:
+9.3%
Share & Embed Analysis
Last updated: April 02, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Eric A Hughes
SELL
9533 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 57 HOLD |
